Newsroom

07 November 2019

New analysis of larger dataset showed that aducanumab has the potential to reduce clinical decline in people diagnosed with early Alzheimer’s disease

Aducanumab is an investigational human monoclonal antibody which has been studied for the treatment of early Alzheimer’s disease. Since October 2017 Biogen and...
30 October 2019

RADAR-AD’s project leader Dag Aarsland talks at the 29th Alzheimer Europe Conference in The Hague “Making valuable connections”

The 29 th Alzheimer Europe Conference (#29AEC) “Making valuable connections” took place on 23th-25 th of October 2019 in The Hague. 954 participants from 46...
14 October 2019

RADAR-AD represented at European Commission’s Research and Innovation Days in Brussels

Our researchers presented the work of RADAR-AD at the exhibition “Science is Wonderful!” on the 25 th and 26 th of September which aimed at bringing science...
21 August 2019

The Neuronet Coordination and Support Action on Neurodegeneration research launches its website

The Neuronet (Efficiently Networking European Neurodegeneration Research) communication team is proud to announce the launch of the official project website:...
17 May 2019

Involving patients in research: the RADAR-AD Patient Advisory Board.

The first steps to create the RADAR-AD Patient Advisory Board (PAB) were taken during the meeting of Alzheimer Europe’s European Working Group of People With...
Press Release
09 May 2019

New Research Consortium Aims to Measure Progression of Alzheimer’s Disease Through Use of Digital Technologies

“A new international consortium of academic and industrial leaders in the field of Alzheimer’s Disease (AD) is pleased to announce the launch of “RADAR-AD” (...
20 February 2019

Project launch: Remote Assessment of Disease and Relapse – Alzheimer’s Disease

RADAR-AD will draw on a wealth of lessons and expertise from people active in the RADAR-CNS and other projects in developing remote measuring technology to be...